Paper Details

  1. Home
  2. Paper Details

Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.

Author: BisgaardHans, BuchvaldFrederik

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effects of salmeterol or montelukast on exhaled nitric oxide (FeNO) levels in asthmatic children who were already taking regular doses of inhaled corticosteroids. The study found that salmeterol was significantly more effective at reducing FeNO levels than either montelukast or placebo. Salmeterol also significantly improved lung function compared to placebo, while montelukast did not show significant improvement compared to placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Inhaled, long-acting beta2-agonists or antileukotrienes are alternatives as add-on therapy for asthmatic children taking regular inhaled steroids. Any complementary effects would be relevant to the choice between these alternatives. Exhaled nitric oxide (FeNO) may reflect these effects. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1081-1206(10)63536-3

データ提供：米国国立医学図書館（NLM）

Salmeterol vs Montelukast in Asthmatic Children

In the field of pediatric pulmonology, managing asthma effectively is paramount. This study investigates the complementary effects of salmeterol and montelukast, two commonly used medications, in asthmatic children already receiving regular inhaled budesonide. The authors employed a randomized, double-blind, double-dummy, crossover study to meticulously compare the effects of these medications on exhaled nitric oxide (FeNO) levels and lung function. The study aimed to provide insights into the relative effectiveness of these treatments and guide clinicians in selecting the most appropriate add-on therapy for asthmatic children. The study concludes that salmeterol, but not montelukast, provided a significant complementary effect on FeNO levels and lung function in asthmatic children already receiving regular budesonide.

Salmeterol's Superior Effect

The study found that salmeterol significantly reduced FeNO levels and improved lung function compared to both placebo and montelukast. This suggests that salmeterol may be a more effective add-on therapy for asthmatic children already receiving regular budesonide. Imagine a camel caravan traversing a desert with varying levels of dust. Salmeterol, like a well-equipped camel, effectively clears the dust, improving air quality for the caravan.

Personalized Asthma Treatment

This study underscores the importance of individualized asthma management. The findings highlight the need to consider the specific needs and characteristics of each patient when selecting add-on therapies. While both salmeterol and montelukast are commonly used, the study suggests that salmeterol may be a more effective option in certain cases.

Dr.Camel's Conclusion

This research provides valuable insights into the complementary effects of salmeterol and montelukast in asthmatic children. The study's findings suggest that salmeterol may be a more effective add-on therapy for certain patients. It emphasizes the importance of personalized asthma management, considering individual needs and characteristics to optimize treatment outcomes.

Date :
  1. Date Completed 2003-11-12
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

14533665

DOI: Digital Object Identifier

10.1016/S1081-1206(10)63536-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.